Results 71 to 80 of about 17,771 (179)

Infection due to Shiga toxin-producing enterohemorrhagic Escherichia coli (EHEC) presenting as ischemic colitis

IDCases, 2019
Infections due to Shiga toxin-producing enterohemorrhagic Escherichia coli (EHEC) are often mild and self-limiting, but more severe cases can develop into hemolytic uremic syndrome (HUS) and hemorrhagic colitis. This case report documents a sporadic case
Camille D. Tanquilut, Chin W. Jung, Allen W. Nelson, Sean K. Lau   +3 more
doaj   +1 more source

Common Hematologic Emergencies—Acute Promyelocytic Leukemia and Microangiopathic Hemolytic Anemias—A Pivotal Role of Clinical Laboratory

International Journal of Laboratory Hematology, Volume 48, Issue 3, Page 521-530, June 2026.
ABSTRACT Hematologic emergencies are urgent health conditions which result in significant mortality and morbidity unless timely therapeutic measures are taken. Therapeutic success depends on their timely and accurate recognition by hematology laboratory services.
Ganna Shestakova, Nicolas Ulrich Edgar, Anton V. Rets   +2 more
wiley   +1 more source

Factors Governing the Cross-Species Virulence of Shiga Toxin-Producing Escherichia coli

Pathogens
Phage-encoded Shiga toxin (Stx) released by Shiga toxin-producing E. coli (STEC) can kill multiple eukaryotic bacterial predators, including Acanthamoeba castellanii, Tetrahymena thermophila and Caenorhabditis elegans.
Paul Hart, Alexander Bowitch, Alexander Mellmann, Denise M. Ferkey, Gerald B. Koudelka   +4 more
doaj   +1 more source

Eculizumab experience in an adult patient with atypical hemolytic uremic syndrome

Saudi Journal of Kidney Diseases and Transplantation, 2017
Atypical hemolytic-uremic syndrome is a disease characterized by nonimmune hemolytic anemia, thrombocytopenia, and renal failure. In this study, we present a case of a patient with atypical hemolytic-uremic syndrome treated successfully with eculizumab ...
Funda Sari, Ayça Inci, Volkan Karakus, Banu Yilmaz, Metin Sarikaya, Refik Olmaz, Erdal Kurtoglu   +6 more
doaj   +1 more source

Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome

Clinical Pharmacology: Advances and Applications, 2011
Maro Ohanian, Christian Cable, Kathleen HalkaDepartment of Hematology and Oncology, Scott and White Healthcare, The Texas A&M Health Science Center College of Medicine, Temple, TX, USAAbstract: This case report describes how eculizumab reversed ...
Ohanian M, Cable CC, Halka KK
doaj  

Hemolytic–Uremic Syndrome in a Grandmother

Emerging Infectious Diseases, 2010
In the spring of 2007, just weeks before my college graduation, my parents called to tell me that my grandmother was sick. I was worried to hear that she was in the hospital, but like the rest of my family, I had little doubt that she’d be better in no time. At a spry 82 years, my grandmother was the picture of health. She was a nonsmoker, a nondrinker,
Lane C. Crawford, Mark L. Crawford, Sean R. Moore   +2 more
openaire   +3 more sources

Recurrent hemolytic uremic syndrome

Indian Journal of Nephrology, 2008
Hemolytic uremic syndrome (HUS) is an uncommon cause of acute renal failure. Diarrhea-associated (D+) HUS, usually seen in children, is a common variety of HUS. HUS that is not associated with diarrhea (D-) is caused by a heterogeneous group of disorders. We report here a case of recurrent HUS (D-) in an adult female with hypocomplementemia.
Lakshminarayana, G., Rajesh, R., Jojo, A., Kurian, G., Unni, V. N.   +4 more
openaire   +2 more sources

Clinical case of thrombotic microangiopathy in obstetric practice

Сеченовский вестник, 2017
Trombotic microangiopathy is heterogeneous group of the diseases united by a community of a histological and clinical implications at difference of pathogenetic mechanisms, presents clinical-morphological syndrome characterizing a lesion of vessels of a ...
M. N. Mochalova, T. E. Belokrinitskaya, T. V. Haven, E. M. Shifman, K. G. Shapovalov, S. V. Kostromitin   +5 more
doaj  

Differential complement activation by alloantibodies in sickle cell hyperhaemolysis syndrome may influence disease course

British Journal of Haematology, Volume 208, Issue 6, Page 2311-2314, June 2026.
Mamie M. Thant, Jahnavi Gollamudi, Stefanie W. Benoit, Satheesh Chonat, Jose A. Cancelas   +4 more
wiley   +1 more source

Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies

Drug Design, Development and Therapy, 2012
Lindsay S Keir,1 Stephen D Marks,2 Jon Jin Kim21Academic Renal Unit, University of Bristol, Bristol; 2Department of Paediatric Nephrology, Great Ormond Street Hospital NHS Foundation Trust, London, United KingdomAbstract: Hemolytic uremic syndrome is the
Keir LS, Marks SD, Kim JJ
doaj